An interventional study of Azithromycin and Methylprednisolone in Idiopathic Pulmonary Fibrosis, sponsored by Assiut University. Recruiting at 2 sites in Egypt. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Assiut University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This randomized controlled trial evaluates the therapeutic role of azithromycin in acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF). Baseline severity classification and stratification were performed using the SCALE-IPF framework (Severity Classification and Lung Evaluation for Prognosis in IPF; locked April 2023) to ensure balanced disease severity across randomized arms. End-of-study analyses included descriptive and stratified phenotyping using the Idiopathic Pulmonary Fibrosis Phenotypes Identification Model (IPIM); locked April 2023).
Following a protocol amendment approved in September 2025, the study expanded into a multi-arm therapeutic platform evaluating both azithromycin timing strategies and combination antifibrotic-immunomodulatory therapy in idiopathic pulmonary fibrosis. Additional treatment arms involving pirfenidone with or without azithromycin were incorporated without altering the original randomized comparisons or baseline study framework.
Both frameworks were developed within the Assiut University IPF Research Program (2022-2026), a coordinated institutional effort investigating clinical, prognostic, and therapeutic dimensions of IPF. Neither framework altered randomization procedures, treatment allocation, or study endpoints; they were applied to improve standardization, reproducibility, and interpretability of results.
This randomized, open-label controlled trial forms part of the Assiut University IPF Research Program (2022-2026). An initial target of 130 patients with clinically mild or early-moderate acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) was specified for enrollment and randomized to receive standard therapy with or without azithromycin.
SCALE-IPF (Severity Classification and Lung Evaluation for Prognosis in IPF; locked April 2023, archived November 2025, digital object identifier [DOI] 10.5281/zenodo.17575973) served as the prespecified baseline severity classification and stratification framework. IPIM (Idiopathic Pulmonary Fibrosis Phenotypes Identification Model; locked April 2023, archived November 2025, DOI 10.5281/zenodo.17576160) was applied as a predefined phenotypic framework integrating clinical, functional, and radiological domains.
Severity and phenotypic frameworks were used exclusively to define eligibility and baseline characterization. They did not influence randomization procedures, treatment allocation, trial conduct, or study endpoints, and were applied to support reproducibility and structured interpretation of therapeutic effects across severity and phenotypic spectra.
Protocol Amendment (September 2025) - Platform Expansion:
To reflect the ongoing institutional clinical ecosystem, the trial was updated via a protocol amendment approved in September 2025 into a multi-arm single-center therapeutic platform. In addition to the original acute exacerbation cohort, the platform expanded to evaluate combination antifibrotic and immunomodulatory therapy targeting the inflammatory phenotype.
Trial enrollment was concurrently expanded to target 250 patients per group. Two additional arms were integrated: Group C (Pirfenidone alone) and Group D (Pirfenidone plus Azithromycin). This expansion allows for two distinct, prespecified therapeutic contrasts from the same institutional infrastructure: an early versus delayed azithromycin intervention (Groups A/B), and a pirfenidone combination therapy concept (Groups C/D).
The platform expansion does not alter the original randomized comparisons, original enrollment chronology, or original study endpoints. SCALE-IPF and IPIM frameworks continue to be utilized for baseline stratification and descriptive phenotyping across all expanded platform arms.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Browse Idiopathic Pulmonary Fibrosis studies →Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive conventional treatment for acute exacerbation of IPF, including pulse corticosteroid therapy and supportive treatment, and oxygen therapy.
Drug: Methylprednisolone
Patients will receive conventional therapy and Add-on Azithromycin 500 mg single daily dose for five days then Patients will receive conventional treatment and early adjunctive azithromycin according to the study treatment protocol. Azithromycin will be administered as a 500 mg oral dose three times weekly during longitudinal follow-up according to tolerability and standard clinical safety monitoring. This arm represents the early inflammatory intervention strategy targeting inflammatory disease behavior in idiopathic pulmonary fibrosis.
Drug: Azithromycin · Drug: Methylprednisolone
Pirfenidone will be administered according to the standard full-dose protocol as 801 mg orally three times daily, corresponding to a total daily dose of 2403 mg/day. This regimen is equivalent to nine 267 mg tablets/capsules per day, given as three tablets/capsules three times daily, according to tolerability and standard safety monitoring.
Drug: Pirfenidone
Patients will receive pirfenidone therapy according to the standard full-dose protocol: 801 mg orally three times daily, equivalent to a total daily dose of 2403 mg/day, administered as three 267 mg tablets/capsules three times daily, combined with adjunctive azithromycin administered as a 500 mg oral dose three times weekly according to the study treatment protocol and standard safety monitoring.
Drug: Azithromycin · Drug: Pirfenidone
A single daily oral dose of azithromycin 500 mg for five days during acute exacerbation, followed by azithromycin 500 mg orally three times weekly as maintenance therapy during longitudinal follow-up according to tolerability and standard clinical safety monitoring.
Also known as: azithromycin 500 mg oral tablet
methylprednisolone 500 mg single intra-venous daily dose for three days
Also known as: methylprednisolone 500 mg
Pirfenidone will be administered according to the standard full-dose protocol as 801 mg orally three times daily, equivalent to a total daily dose of 2403 mg/day, administered as three 267 mg tablets/capsules three times daily according to tolerability and standard clinical safety monitoring.
Also known as: Pirfenidone 267 mg oral tablet/capsule
Hospital stay
the main aim of the study to assess the hospital stay expressed in days in the Add-on Azithromycin 500 mg single oral daily dose in comparison to the conventional therapy group only
Time frame: 5-10 Days ( Days of Hospital admission until improvement and discharge)
Change in clinical outcome measures stratified by SCALE-IPF severity
Evaluate the treatment response and short-term progression of AE-IPF patients across baseline severity strata as defined by the SCALE-IPF classification (locked April 2023). Outcomes include improvement in oxygenation, radiological resolution, and need for hospitalization. This will assess whether baseline SCALE-IPF strata correlate with therapeutic response and clinical stability.
Time frame: From randomization (Day 1) to Month 3 post-enrollment.
Association between SCALE-IPF severity and one-year mortality
Determine whether baseline SCALE-IPF severity independently predicts 12-month all-cause mortality following acute exacerbation in both treatment arms. This analysis provides validation of the SCALE-IPF prognostic gradient within a randomized framework.
Time frame: Baseline to 12 months post-randomization.
Correlation between azithromycin response and IPIM phenotypic clusters
Analysis comparing treatment outcomes across IPIM-defined phenotypic clusters
Time frame: Baseline to 12 months post-randomization.
Event-free survival across SCALE-IPF strata
Compare event-free survival (freedom from recurrent AE, hospitalization, or death) between azithromycin and control groups across SCALE-defined severity categories.
Time frame: Baseline to 12 months post-randomization.
Analytical validation of SCALE-IPF and IPIM within the randomized AE-IPF cohort
Evaluate the performance, calibration, and clinical concordance of the two institutional frameworks-SCALE-IPF (randomization classifier) and IPIM (descriptive phenotype model)-within the azithromycin randomized trial population.
Time frame: Baseline to 12 months post-randomization.
Exacerbation frequency in the pirfenidone combination therapy domain
Comparison of acute exacerbation frequency between the Pirfenidone Therapy arm and the Pirfenidone Plus Azithromycin Therapy arm during longitudinal follow-up. Unit of Measure: Number of exacerbation events per participant.
Time frame: Baseline to Month 12 post-randomization.
Forced vital capacity decline in the pirfenidone combination therapy domain
Comparison of longitudinal forced vital capacity decline between the Pirfenidone Therapy arm and the Pirfenidone Plus Azithromycin Therapy arm. Unit of Measure: Forced vital capacity (% predicted).
Time frame: Baseline to Month 12 post-randomization.
Hospitalization frequency in the pirfenidone combination therapy domain
Comparison of hospitalization frequency related to respiratory deterioration between the Pirfenidone Therapy arm and the Pirfenidone Plus Azithromycin Therapy arm. Unit of Measure: Percentage of participants.
Time frame: Baseline to Month 12 post-randomization.
Mortality in the pirfenidone combination therapy domain
Comparison of all-cause mortality between the Pirfenidone Therapy arm and the Pirfenidone Plus Azithromycin Therapy arm during longitudinal follow-up. Unit of Measure: Percentage of participants.
Time frame: Baseline to Month 12 post-randomization.
Event-free survival in the azithromycin timing intervention domain
Comparison of event-free survival between the Conventional/Delayed Azithromycin Strategy arm and the Early Azithromycin Strategy arm. Unit of Measure: Time-to-event outcome (days).
Time frame: Baseline to Month 12 post-randomization.
Disease progression in the azithromycin timing intervention domain
Comparison of longitudinal disease progression between the Conventional/Delayed Azithromycin Strategy arm and the Early Azithromycin Strategy arm. Unit of Measure: Percentage of participants with clinical progression.
Time frame: Baseline to Month 12 post-randomization.
SCALE-IPF stratified clinical outcomes across therapeutic platform arms
Assessment of clinical outcomes across predefined SCALE-IPF (severity classification and lung evaluation for prognosis in idiopathic pulmonary fibrosis score) severity strata within all therapeutic platform arms. Unit of Measure: Percentage of participants.
Time frame: Baseline to Month 12 post-randomization.
IPIM phenotype-treatment interaction across therapeutic platform arms
Assessment of treatment-response variation across IPIM-defined phenotypic groups within all therapeutic platform arms. Unit of Measure: Percentage of participants.
Time frame: Baseline to Month 12 post-randomization.
C-reactive protein levels in the pirfenidone combination therapy domain
Comparison of longitudinal C-reactive protein levels between the Pirfenidone Therapy arm and the Pirfenidone Plus Azithromycin Therapy arm during follow-up. Unit of Measure: C-reactive protein (mg/L).
Time frame: Baseline to Month 12 post-randomization.
Indirect mediation effect of C-reactive protein on azithromycin-associated clinical progression across platform arms
Assessment of the indirect mediation effect of longitudinal C-reactive protein change on the association between azithromycin exposure and clinical progression across therapeutic platform arms using mediation analysis. Unit of Measure: Standardized indirect mediation effect estimate.
Time frame: Baseline to Month 12 post-randomization.
Joint modeling of forced vital capacity decline and acute exacerbation risk across platform arms
Assessment of the association between longitudinal forced vital capacity decline and acute exacerbation risk across therapeutic platform arms using joint longitudinal-event modeling. Unit of Measure: Joint model association estimate.
Time frame: Baseline to Month 12 post-randomization.
Joint modeling of oxygen saturation decline and acute exacerbation risk across platform arms
Assessment of the association between longitudinal oxygen saturation decline and acute exacerbation risk across therapeutic platform arms using joint longitudinal-event modeling. Unit of Measure: Joint model association estimate.
Time frame: Baseline to Month 12 post-randomization.
Joint modeling of C-reactive protein change and acute exacerbation risk across platform arms
Assessment of the association between longitudinal C-reactive protein change and acute exacerbation risk across therapeutic platform arms using joint longitudinal-event modeling. Unit of Measure: Joint model association estimate.
Time frame: Baseline to Month 12 post-randomization.
Effect size of azithromycin exposure on clinical progression across platform arms
Estimation of the standardized effect size for the association between azithromycin exposure and clinical progression across therapeutic platform arms. Unit of Measure: Standardized effect size.
Time frame: Baseline to Month 12 post-randomization.
Change-point analysis of azithromycin-associated clinical progression across platform arms
Assessment of temporal change-points in clinical progression patterns associated with azithromycin exposure across therapeutic platform arms using longitudinal change-point analysis. Unit of Measure: Estimated temporal change-point (days).
Time frame: Baseline to Month 12 post-randomization.
Longitudinal modeling of clinical progression across therapeutic platform arms
Assessment of longitudinal clinical progression trajectories across therapeutic platform arms using repeated-measures longitudinal modeling. Unit of Measure: Longitudinal trajectory model estimate.
Time frame: Baseline to Month 12 post-randomization.
Regression analysis of predictors of clinical progression across platform arms
Assessment of clinical, physiological, and inflammatory predictors of longitudinal clinical progression across therapeutic platform arms using regression analysis. Unit of Measure: Regression coefficient estimate.
Time frame: Baseline to Month 12 post-randomization.
Correlation analysis of C-reactive protein change and forced vital capacity decline across platform arms
Assessment of the correlation between longitudinal C-reactive protein change and forced vital capacity decline across therapeutic platform arms. Unit of Measure: Correlation coefficient.
Time frame: Baseline to Month 12 post-randomization.
Longitudinal oxygen saturation change in the pirfenidone combination therapy domain
Comparison of longitudinal oxygen saturation change between the Pirfenidone Therapy arm and the Pirfenidone Plus Azithromycin Therapy arm during follow-up. Unit of Measure: Oxygen saturation (%).
Time frame: Baseline to Month 12 post-randomization.
Treatment tolerability in the pirfenidone combination therapy domain
Comparison of treatment tolerability and drug-related adverse effects between the Pirfenidone Therapy arm and the Pirfenidone Plus Azithromycin Therapy arm during follow-up. Unit of Measure: Percentage of participants with treatment-related adverse events.
Time frame: Baseline to Month 12 post-randomization.
Health-related quality of life change across therapeutic platform arms
Assessment of longitudinal change in King's Brief Interstitial Lung Disease (K-BILD) questionnaire scores across therapeutic platform arms. The K-BILD score ranges from 0 to 100, with higher scores indicating better health-related quality of life. Unit of Measure: K-BILD score (0-100 scale).
Time frame: Baseline to Month 12 post-randomization.
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Jan 2027, 43 months after the start.
Of 49 non-industry interventional studies with no phase under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 53. This study's planned 43 months is above that.
Counting every sponsor, half of 52 studies reached it within 26 months; a quarter within 12 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Azithromycin · Methylprednisolone · Pirfenidone
Idiopathic Pulmonary Fibrosis →